Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF) Sets New 1-Year High – Here’s What Happened

Recordati Industria Chimica e Farmaceutica S.p.A. (OTCMKTS:RCDTF) shares reached a new 52-week high on Tuesday . The stock traded as high as $52.25 and last traded at $52.25, with a volume of 0 shares traded. The stock had previously closed at $52.25.

Analysts Set New Price Targets

Separately, Royal Bank of Canada upgraded Recordati Industria Chimica e Farmaceutica to a “hold” rating in a report on Monday, October 7th.

Recordati Industria Chimica e Farmaceutica Stock Performance

The stock has a market cap of $10.78 billion, a price-to-earnings ratio of 26.13 and a beta of 0.33. The business’s 50 day moving average is $52.25 and its 200 day moving average is $51.85. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.36 and a quick ratio of 0.95.

Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF) last announced its quarterly earnings results on Tuesday, July 30th. The company reported $0.70 earnings per share (EPS) for the quarter. Recordati Industria Chimica e Farmaceutica had a net margin of 17.41% and a return on equity of 30.78%. The business had revenue of $622.00 million during the quarter.

Recordati Industria Chimica e Farmaceutica Company Profile

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis.